↓ Skip to main content

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells

Overview of attention for article published in Frontiers in Pharmacology, October 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
Published in
Frontiers in Pharmacology, October 2018
DOI 10.3389/fphar.2018.01097
Pubmed ID
Authors

Wei Zhang, Ying-Fang Fan, Chao-Yun Cai, Jing-Quan Wang, Qiu-Xu Teng, Zi-Ning Lei, Leli Zeng, Pranav Gupta, Zhe-Sheng Chen

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 27%
Student > Doctoral Student 3 14%
Unspecified 2 9%
Student > Bachelor 2 9%
Professor 1 5%
Other 3 14%
Unknown 5 23%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 6 27%
Biochemistry, Genetics and Molecular Biology 3 14%
Unspecified 2 9%
Agricultural and Biological Sciences 2 9%
Sports and Recreations 1 5%
Other 1 5%
Unknown 7 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2018.
All research outputs
#20,537,234
of 23,108,064 outputs
Outputs from Frontiers in Pharmacology
#10,332
of 16,462 outputs
Outputs of similar age
#300,885
of 346,174 outputs
Outputs of similar age from Frontiers in Pharmacology
#297
of 407 outputs
Altmetric has tracked 23,108,064 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,462 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,174 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 407 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.